Edition:
India

Hansa Biopharma AB (HNSA.ST)

HNSA.ST on Stockholm Stock Exchange

149.00SEK
18 Sep 2019
Change (% chg)

1.10kr (+0.74%)
Prev Close
147.90kr
Open
151.10kr
Day's High
152.00kr
Day's Low
146.10kr
Volume
159,990
Avg. Vol
125,003
52-wk High
349.40kr
52-wk Low
138.30kr

Summary

Name Age Since Current Position

Ulf Wiinberg

60 2018 Independent Chairman of the Board

Soeren Tulstrup

54 2018 President, Chief Executive Officer

Donato Spota

2019 Chief Financial Officer, Senior Vice President

Christian Kjellman

52 2019 Senior Vice President, Chief Scientific Officer, Research and Development

Henk Doude van Troostwijk

54 2019 Senior Vice President, Chief Commercial Officer

Eva-Maria Joed

50 2019 Vice President, Finance & Administration

Anne Safstrom Lanner

50 2019 Vice President, Global Human Resources

Karin Aschan

58 2016 Vice President, Regulatory Affairs

Vincenza Nigro

56 2018 Vice President, Global Medical Affairs

Max Sakajja

38 2017 Vice President, Corporate Strategy

Emanuel Bjorne

46 2019 Vice President Global Business Development

Mats Blom

54 2019 Director

Eva Nilsagard

55 2019 Director

Andreas Eggert

52 2018 Independent Director

Anders Gersel Pedersen

67 2018 Independent Director

Birgit Stattin Norinder

71 2018 Independent Director

Klaus Sindahl

2019 Head of Investor Relations

Biographies

Name Description

Ulf Wiinberg

Mr. Ulf Wiinberg has been Independent Chairman of the Board of Directors at Hansa Biopharma AB (previously Hansa Medical AB) since March 20, 2018. He was Acting Chief Executive Officer and Director of the Company from November 9, 2017 till March 20, 2018. He has previously been Independent Chairman of the Board of Directors of Hansa Medical AB since May 11, 2016. He is an experienced healthcare industry professional who has served the boards of several healthcare industry associations. At Wyeth, he has been both President of the global consumer health care business and President for the European pharma business, and he has also held the position as CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Ulf is a non-executive Board member at Alfa Laval AB, Agenus Inc and UCB. He is also Chairman of Sigrid Therapeutics AB. He also serves as CEO and Chairman of Ulf Wiinberg consulting&invest AB, as well as CEO for X-Vax Technologies Inc in Jupiter Florida.

Soeren Tulstrup

Mr. Soeren Tulstrup has been President and Chief Executive Officer of Hansa Biopharma AB since March 20, 2018. He has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG. Prior to joining Vifor Pharma, he served as Senior Vice President, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase (INN: Idursulfase), an enzyme-based treatment of the rare disease Hunter syndrome. He has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA -targeted drugs for various therapeutic areas including cancer and rare genetic diseases. Furthermore, he has served in several senior commercial roles within Merck & Co., Inc. and Sandoz Pharma AG (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School.

Donato Spota

Mr. Donato Spota has been Chief Financial Officer, Senior Vice President at Hansa Biopharma AB since May 15, 2019. He has more than 20 years of pharmaceutical industry experience in international environments, including strategic finance, investor relations and international capital markets transactions to the company. Prior to joining Hansa, Donato served as Chief Financial Officer at Basilea Pharmaceutica AG. Donato holds a degree in Information Technology from the Swiss BBT (Bundesamt fuer Berufsbildung und Technologie) and a master’s degree in business administration from the Hochschule fuer Wirtschaft und Umwelt Nuertingen-Geislingen.

Christian Kjellman

Dr. Christian Kjellman, Ph.D. has served as Senior Vice President, Chief Scientific Officer, Research and Development at Hansa Biopharma AB since 2019. He previously was Senior Vice President, Research and Development at Hansa Biopharma AB (previously Hansa Medical AB). He has previously served as Chief Scientific Officer at the Company since 2008. He was previously Senior Scientist at BioInvent AB. Prior to that, he was Head of Research at Cartela AB, mainly focusing on novel drug target evaluation. He has experience as Researcher in Cell and Molecular Biology and as Assistant Professor in Molecular Genetics at Lunds Universitet (Lund University). He holds Master of Science degree in Chemical Biology and Doctorate in Philosophy degree in Tumor Immunology, both from Lunds Universitet.

Henk Doude van Troostwijk

Mr. Henk J. Doude van Troostwijk has served as Senior Vice President, Chief Commercial Officer at Hansa Biopharma AB since 2019. He has previously been Vice President, Commercial Operations at Hansa Biopharma AB (previously Hansa Medical AB) since May 12, 2016. He has management experience in sales and marketing from the areas of transplantation and orphan drugs. Before joining Hansa Medical in 2016, Henk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk holds an MBA from Henley Management College at the University of Reading, UK.

Eva-Maria Joed

Ms. Eva-Maria Joed has been appointed Vice President, Finance & Administration at Hansa Biopharma AB, effective as of May 15, 2019. She no longer serves as Vice President and Chief Financial Officer of the Company effective as of May 15, 2019. She has held the position since 2015. Eva-Maria joined Hansa Medical in 2015 and has long and wide experience within finance. She has held positions both as Chief Accountant and CFO and worked in international companies such as Kemira Kemi AB, Johns Manville AB within the Berkshire Hathaway group and Procordia Food AB. She has also been responsible for implementing new financial systems and policies, and for IT. Eva-Maria holds Master of Science in Business and Economics from Lund University.

Anne Safstrom Lanner

Ms. Anne Safstrom Lanner has been Vice President, Global Human Resources at Hansa Biopharma AB since January 2019. Anne joined Hansa Biopharma after having served at European Spallation Source (ESS), a joint European multi-disciplinary research facility and at Cellavision, a provider of digital solutions for medical microscopy within hematology. She has held positions both as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has experience from growing start-up international companies. Anne holds a Bachelor of Social Science in Human Resource Management, focusing in organizational development & leadership, from Lund University.

Karin Aschan

Ms. Karin Aschan has been Vice President, Regulatory Affairs at Hansa Biopharma AB (previously Hansa Medical AB) since the third quarter of 2016. She has a long experience from working within Regulatory Affairs, initially at Astra Zeneca, and has worked on EU and US projects in all phases through the first clinical study up to marketing phase. Karin has held the position as Head of Regulatory Affairs at Active Biotech and at Clinical Data Care. She has also been working as an independent regulatory consultant. Karin holds M.Sc. in Pharmacy from Uppsala University.

Vincenza Nigro

Ms. Vincenza Nigro has been Vice President, Global Medical Affairs at Hansa Biopharma AB (previously Hansa Medical AB) since September 17, 2018. She holds more than two decades of international, life sciences industry expertise in medical affairs, clinical development and commercial leadership roles, including deep experience in transplantation and orphan diseases. Before joining Hansa Biopharma in 2018, Vincenza built and led the global medical affairs function at Veloxis Pharmaceuticals, a specialty pharmaceutical company focused on transplantation. Previously, she spent over a decade at Hoffmann- La Roche in the US in drug discovery, clinical development and commercial roles within immunology and transplantation. She has also held a commercial leadership role at US specialty pharma company Enzon Pharmaceuticals, which was focused on oncology. Ms. Nigro holds an MBA degree from Massachusetts Institute of Technology (MIT).

Max Sakajja

Mr. Max Sakajja has been Vice President, Corporate Strategy at Hansa Biopharma AB (previously Hansa Medical AB) since 2017. He has a broad background in corporate development, strategy and finance. He has previously worked with corporate finance at Swedish Orphan Biovitrum AB (SOBI) in the position of Director Mergers & Acquisitions. Before joining Hansa Biopharma, Max worked as the Global Product and Service Development Manager at Envirotainer. Max has also worked as an independent management consultant providing advisory services to the Scandinavian life science industry. Max holds an M.Sc. in Molecular Biotechnology from the Royal Institute of Technology.

Emanuel Bjorne

Mr. Emanuel Bjorne has served as Vice President Global Business Development at Hansa Biopharma AB since 2019. He has previously been Vice President, Business Development and Investor Relations at Hansa Biopharma AB (previously Hansa Medical AB). He was Corporate Development Director at the Company from November 25, 2014. He was Chief Executive Officer (CEO) of Hansa Medical AB from 2007 until November 25, 2014. He was previously Scientific Project Manager focused on Business Intelligence and Analysis within Pharmaceuticals, Diagnostics and Analytical Instrumentation at Biolin Scientific. Prior to that, he was Analytical Development Chemist at PolyPeptide Labs, focusing on the development of analytical methods based on Mass Spectrometry and Chromatography for peptide drugs in early clinical stage. Previously, he was Member of the Board at Cartela i Malmo AB, and he was Deputy Member of the Board of Directors and CEO of Hansa Medical Utvecklings AB. He holds Master of Science degree in Engineering Physics, focusing on Biophysical Chemistry from both Lunds Universitet (Lund University) and the University of California at Santa Barbara, the United States.

Mats Blom

Mr. Mats Peter Blom has been Director of Hansa Biopharma AB since May 22, 2019. He has extensive managerial experience and is Chief Financial Officer (CFO) of Modus Therapeutics AB. Prior to joining Modus, he served as CFO of Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has held CFO positions at Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.

Eva Nilsagard

Ms. Eva Nilsagard has been Director of Hansa Biopharma AB since May 22, 2019. She is currently interim CFO at OptiGroup AB and founder and CEO of Nilsagard Consulting AB. She has served as CFO of Vitrolife and Plastal, Senior Vice President Strategy & Business Development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva is a board member and chairman of the audit committee of Addlife, Bufab, Irras and Xbrane Biopharma, and board member of SEK (Swedish Export Credit Company). Eva has more than ten years of experience as a mentor for young female managers with high potential. Eva Nilsagard holds an Executive MBA in Economics and a Bsc in accounting and finance from School of Business, Economics and Law in Gothenburg.

Andreas Eggert

Mr. Andreas Eggert has been Independent Director of Hansa Biopharma AB (previously Hansa Medical AB) since May 29, 2018. Andreas has more than 20 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. He is COO at X-Vax Technology Inc. in the US. He served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and member of the Corporate Management Committee at H. Lundbeck A/S in Denmark, where he was responsible for multiple new product launches and the commercial leadership for shaping the product portfolio and development pipeline. Previously, Andreas served as Vice President & Global Business Manager at Wyeth/Pfizer in the US. He held several senior commercial positions for Wyeth in the US, Japan and in Germany. Andreas also was a management consultant at A.T. Kearney. He holds an MBA from Azusa Pacific University.

Anders Gersel Pedersen

Dr. Anders Gersel Pedersen, M.D., Ph.D. has been Independent Director of Hansa Biopharma AB (previously Hansa Medical AB) since May 29, 2018. He is Chairman of the Scientific Committee and Member of the Remuneration Committee. Anders has a long experience from the international pharmaceutical industry. Following his degree in medicine and research fellow positions at Copenhagen hospitals, he worked for Eli Lilly for 11 years. In January 2000 he joined H. Lundbeck A/S in Denmark and is currently Executive Vice President of the Research & Development organization, hence responsible for the discovery and development of the product pipeline from pre-clinical activities to post-launch marketing studies. He serves on the supervisory boards of Bavarian Nordic A/S (deputy chairman) and Genmab A/S. Anders received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School.

Birgit Stattin Norinder

Ms. Birgit Stattin Norinder has served as Independent Member of the Board of Directors at Hansa Biopharma AB (previously Hansa Medical AB) since March 20, 2018. She was Chairman of the Board from November 9, 2017 till March 20, 2018. She has previously been Independent Member of the Board of Directors of Hansa Medical AB from May 11, 2016 till November 8, 2017. She was previously Independent Chairman of the Board of Directors at the Company from September 2014 until May 11, 2016. She has been Member of the Company's Board since May 14, 2012. She is Chairman of the Remuneration Committee and Member of the Audit Committee as well as the Scientific Committee of the Company. She has experience from international pharmaceutical and biotechnology companies in Sweden, the United States and the United Kingdom (UK). She has managed several research and development departments. She has also served as Chief Executive Officer and Chairman at Prolifix Ltd., Senior Vice President of Worldwide Product Development at Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division at Glaxo Group Research Ltd. She has also held several Board and Chairman positions at UK, Swedish and Norwegian biotechnology companies. She is Member of the Boards of AddLife AB and Jettesta AB. She was Chairman of the Board of Directors of Wingfirm Pharma AB, Partners for Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB and Index Pharmaceutical AB, as well as Board Member of Karo Bio Aktiebolag and Antisoma Plc. She holds a Master of Science degree in Pharmacy from Uppsala Universitet (Uppsala University).

Klaus Sindahl